<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162353</url>
  </required_header>
  <id_info>
    <org_study_id>ICG185-001</org_study_id>
    <nct_id>NCT04162353</nct_id>
  </id_info>
  <brief_title>BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma</brief_title>
  <official_title>BCMA-CD19 cCAR in Relapsed and /or Refractory Multiple Myeloma and Plasmacytoid Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iCell Gene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iCAR Bio, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iCell Gene Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, interventional, single arm, open label, treatment study to evaluate the
      safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory
      multiple myeloma and plasmacytoid lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BCMA-CD19 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct
      functional CAR molecules expressing on a T-cell, directed against the surface proteins BCMA
      and CD19. BCMA-CD19 cCAR is also aimed to treat multiple myeloma, a challenging disease due
      to the heterogeneity of myeloma cells, which renders single-antigen targeting CAR T-cell
      therapy ineffective. BCMA-CD19 cCAR is proposed to target both bulky myeloma cells expressing
      BCMA, and myeloma stem cells expressing CD19 to effectively eradicate the disease.

      BCMA-CD19 cCAR is also aimed to treat heterogeneous plasmacytoid lymphoma bearing two types
      of lymphoma cells, regular lymphoma cells expressing CD19 and plasmacytoid lymphoma cells
      expressing BCMA. The use of two different targets intends to increase coverage and eradicate
      cancerous cells before resistance develops in surviving cancer cells that have undergone
      selective pressures or antigen escape.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events after BCMA-CD19 cCAR T cells infusion</measure>
    <time_frame>2 years particularly the first 28 days after infusion</time_frame>
    <description>Determine the toxicity profile of BCMA-CD19 cCAR T cell therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>For multiple myeloma - Stringent complete response</measure>
    <time_frame>24 months</time_frame>
    <description>Stringent complete response (sCR) (IMWG criteria)</description>
  </other_outcome>
  <other_outcome>
    <measure>For multiple myeloma - Complete response (CR)</measure>
    <time_frame>24 months</time_frame>
    <description>Complete response (CR) (IMWG criteria)</description>
  </other_outcome>
  <other_outcome>
    <measure>For multiple myeloma - Very good partial response (VGPR)</measure>
    <time_frame>24 months</time_frame>
    <description>Very good partial response (VGPR) (IMWG criteria)</description>
  </other_outcome>
  <other_outcome>
    <measure>For multiple myeloma - Partial response (PR)</measure>
    <time_frame>24 months</time_frame>
    <description>Partial response (PR) (IMWG criteria)</description>
  </other_outcome>
  <other_outcome>
    <measure>For multiple myeloma - Minimal response (MR)</measure>
    <time_frame>24 months</time_frame>
    <description>Minimal response (MR) (IMWG criteria)</description>
  </other_outcome>
  <other_outcome>
    <measure>For multiple myeloma - Stable disease (SD)</measure>
    <time_frame>24 months</time_frame>
    <description>Stable disease (SD) (IMWG criteria)</description>
  </other_outcome>
  <other_outcome>
    <measure>For multiple myeloma - Progressive disease (PD)</measure>
    <time_frame>12 months</time_frame>
    <description>Progressive disease (PD) (IMWG criteria)</description>
  </other_outcome>
  <other_outcome>
    <measure>For multiple myeloma - Progression-free survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Progression-free survival (PFS) (IMWG criteria)</description>
  </other_outcome>
  <other_outcome>
    <measure>For plasmacytoid lymphoma - Assessment of morphologic CR, CR1, no residual disease, and molecular remission</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of morphologic complete remission (CR), complete remission with incomplete recovery of counts (CR1), no residual disease as analyzed by flow cytometry analysis, and molecular remission by molecular studies</description>
  </other_outcome>
  <other_outcome>
    <measure>For plasmacytoid lymphoma - Progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival (PFS)</description>
  </other_outcome>
  <other_outcome>
    <measure>For plasmacytoid lymphoma - Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Plasmacytoid; Lymphoma</condition>
  <arm_group>
    <arm_group_label>BCMA-CD19 cCAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCMA-CD19 cCAR T cells</intervention_name>
    <description>BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy</description>
    <arm_group_label>BCMA-CD19 cCAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent; Patients volunteer to participate in the research

          -  Diagnosis is mainly based on the World Health Organization (WHO) 2008

          -  Patients have exhausted standard therapeutic options

          -  Systematic usage of immunosuppressive drug or corticosteroid must have been stopped
             for more than 1 weeks

          -  Female must be not pregnant during the study

        Exclusion Criteria:

          -  Patients declining to consent for treatment

          -  Prior solid organ transplantation

          -  Potentially curative therapy including chemotherapy or hematopoietic cell transplant

          -  Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyu Zhang, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fang Liu, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chengdu Military General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Pinz, MS</last_name>
    <phone>6315386218</phone>
    <email>kevin.pinz@icellgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital, China</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Zhang, MD/PhD</last_name>
      <email>Hongyu.Zhang@pkuszh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chengdu Military General Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Liu, MD/PhD</last_name>
      <email>lfyh2006@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCMA</keyword>
  <keyword>CD19</keyword>
  <keyword>BCMA-CD19 cCAR T cells</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>plasmacytoid lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

